3-bromopyruvate: Targets and outcomes

Journal of Bioenergetics and Biomembranes

Volumn 44, Issue 1, 2012, Pages 7-15

  Shoshan, Maria C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

3 bromopyruvate; Cancer; Chemotherapy; Energy metabolism; toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATE; BROMOPYRUVIC ACID; CISPLATIN; DNA; FLUOROURACIL; HEXOKINASE; LACTATE DEHYDROGENASE; OXALIPLATIN; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; PYRUVIC ACID DERIVATIVE; RNA; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

CANCER CELL; CANCER RESISTANCE; CYTOSOL; CYTOTOXICITY; DNA ALKYLATION; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME DEGRADATION; GLYCOLYSIS; HUMAN; MITOCHONDRION; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS, ALKYLATING; ENERGY METABOLISM; GLYCOLYSIS; HEXOKINASE; L-LACTATE DEHYDROGENASE; NEOPLASMS; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATES;

ANIMALIA;

EID: 84858704865     PISSN: 0145479X     EISSN: 15736881     Source Type: Journal    
DOI: 10.1007/s10863-012-9419-2     Document Type: Short Survey

References (78)

1. Apfel MA, Ikeda BH, Speckhard DC, Frey PA (1984) Escherichia coli pyruvate dehydrogenase complex. Thiamin pyrophosphate-dependent inactivation by 3-bromopyruvate. J Biol Chem 259:2905-2909 (Pubitemid 14127923)
2. Banas T, Gontero B, Drews VL, Johnson SL, Marcus F, Kemp RG (1988) Reactivity of the thiol groups of Escherichia coli phosphofructo-1-kinase. Biochim Biophys Acta 957:178-184
3. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19:17-24
4. Dell'Antone P (2009) Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Med Chem 5:491-496
5. Ganapathy-Kanniappan S, Vali M, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Geschwind JF (2010a) 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol 11:510-517
6. da Silva AP Pereira, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT, Galina A (2009) Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417:717-726
7. Dell'Antone P (2006) Inactivation of H+-vacuolar ATPase by the energy blocker 3-bromopyruvate, a new antitumour agent. Life Sci 79:2049-2055
8. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909-3913 (Pubitemid 34791050)
9. Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83-91 (Pubitemid 32907513)
10. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL (2004) Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269-275 (Pubitemid 39311489)
11. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777-4786 (Pubitemid 44187625)
12. Mathupala SP, Ko YH, Pedersen PL (2010) The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797:1225-1230
13. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N (2010) VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 31:227-285
14. Ramsay EE, Hogg PJ, Dilda PJ (2011) Mitochondrial metabolism inhibitors for cancer therapy. Pharm Res 28:2731-2744
15. Pastorino JG, Hoek JB (2003) Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr Med Chem 10:1535-1551 (Pubitemid 36896555)
16. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633-4646 (Pubitemid 44187614)
17. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
18. Tennant DA, Duran RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10:267-277
19. Shoshan-Barmatz V, Ben-Hail D: VDAC, a multi-functional mitochondrial protein as a pharmacological target, Mitochondrion 2011,
20. Chen Z, Zhang H, Lu W, Huang P (2009) Role of mitochondriaassociated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787:553-560
21. Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, Kim SJ, Park JH (2008) Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 40:607-618
22. Vahsen N, Cande C, Briere JJ, Benit P, Joza N, Larochette N, Mastroberardino PG, Pequignot MO, Casares N, Lazar V, Feraud O, Debili N, Wissing S, Engelhardt S, Madeo F, Piacentini M, Penninger JM, Schagger H, Rustin P, Kroemer G (2004) AIF deficiency compromises oxidative phosphorylation. EMBO J 23:4679-4689 (Pubitemid 39657867)
23. Porter AG, Urbano AG (2006) Does apoptosis-inducing factor (AIF) have both life and death functions in cells? Bioessays 28:834-843 (Pubitemid 44433745)
24. Joza N, Pospisilik JA, Hangen E, Hanada T, Modjtahedi N, Penninger JM, Kroemer G (2009) AIF: not just an apoptosis-inducing factor. Ann N Y Acad Sci 1171:2-11
25. Sevrioukova IF (2011) Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal 14:2545-2579
26. Penso J, Beitner R (1998) Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 342:113-117 (Pubitemid 28131352)
27. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N (2004) Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16:819-830 (Pubitemid 39586539)
28. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, Bronner V, Notcovich A, Shoshan-Barmatz V, Flescher E (2008) Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27:4636-4643
29. Pastorino JG, Shulga N, Hoek JB (2002) Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277:7610-7618 (Pubitemid 34953160)
30. Shulga N, Wilson-Smith R, Pastorino JG (2009) Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 8:3355-3364
31. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S (2007) Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120:175-180 (Pubitemid 44901933)
32. Ihrlund LS, Hernlund E, Khan O, Shoshan MC (2008) 3-bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Molecular Oncology 2:94-101
33. Aram L, Geula S, Arbel N, Shoshan-Barmatz V (2010) VDAC1 cysteine residues: topology and function in channel activity and apoptosis. Biochem J 427:445-454
34. Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V (2008) Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding. J Biol Chem 283:13482-13490
35. Halestrap AP, McStay GP, Clarke SJ (2002) The permeability transition pore complex: another view. Biochimie 84:153-166
36. Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G (2000) Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19:307-314 (Pubitemid 30077228)
37. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M (2009) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 29:4909-4918
38. Jones AR, Porter KE, Dobbie MS (1996) Renal and spermatozoal toxicity of alpha-bromohydrin, 3-bromolactate and 3-bromopyruvate. J Appl Toxicol 16:57-63 (Pubitemid 26041579)
39. Sirover MA (2005) New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J Cell Biochem 95:45-52 (Pubitemid 41420214)
40. Hara MR, Cascio MB, Sawa A (2006) GAPDH as a sensor of NO stress. Biochim Biophys Acta 1762:502-509
41. Yun SL, Suelter CH (1979) Modification of yeast pyruvate kinase by an active site-directed reagent, bromopyruvate. J Biol Chem 254:1811-1815
42. Acan NL, Ozer N (2001) Modification of human erythrocyte pyruvate kinase by an active site-directed reagent: bromopyruvate. J Enzyme Inhib 16:457-464 (Pubitemid 34071689)
43. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sanchez R (2010) Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31:29-59
44. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED (2007) A mitochondria-K+channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37-51
45. Pan JG, Mak TW: Metabolic targeting as an anticancer strategy: dawn of a new era?, Sci STKE 2007, 2007:pe14
46. Papandreou I, Goliasova T, Denko NC (2011) Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm? Int J Cancer 128:1001-1008
47. Korotchkina LG (1999) Showkat Ali M, Patel MS: Involvement of alpha-cysteine-62 and beta-tryptophan-135 in human pyruvate dehydrogenase catalysis. Arch Biochem Biophys 369:277-287
48. Kumar V, Kota V, Shivaji S (2008) Hamster sperm capacitation: role of pyruvate dehydrogenase A and dihydrolipoamide dehydrogenase. Biol Reprod 79:190-199
49. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-3942
50. Neuzil J, Dyason JC, Freeman R, Dong LF, Prochazka L, Wang XF, Scheffler I, Ralph SJ (2007) Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 39:65-72 (Pubitemid 46877173)
51. Qin JZ, Xin H, Nickoloff BJ (2010) 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun 396:495-500
52. Macchioni L, Davidescu M, Sciaccaluga M, Marchetti C, Migliorati G, Coaccioli S, Roberti R, Corazzi L, Castigli E (2011) Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells. J Bioenerg Biomembr 43:507-518
53. White E, DiPaola RS (2009) The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 15:5308-5316
54. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M (2010b) 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res 30:923-935
55. Zhao H, Tanaka T, Halicka HD, Traganos F, Zarebski M, Dobrucki J, Darzynkiewicz Z (2007) Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes. Cytometry A 71:905-914 (Pubitemid 350076854)
56. Sanchez-Arago M, Cuezva JM (2011) The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 9:19
57. Nakano A, Tsuji D, Miki H, Cui Q, Sayed SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa K, Takeuchi K, Sakai A, Ozaki S, OkanoK, Nakamura T, Itoh K,Matsumoto T, Abe M (2011) Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells. PLoS One 6:e27222
58. Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, Widger W, Ellis LM, Weihua Z: Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells, Cancer Res 2011
59. Cao X, Jia G, Zhang T, Yang M, Wang B, Wassenaar PA, Cheng H, Knopp MV, Sun D (2008) Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol 62:985-994
60. Pinheiro C, Longatto-Filho A, Pereira SM, Etlinger D, Moreira MA, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2009) Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Dis Markers 26:97-103
61. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F (2010) Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010:427694
62. Chiche J, Brahimi-Horn MC, Pouyssegur J: Tumor hypoxia induces a metabolic shift causing acidosis: a common feature in cancer, J Cell Mol Med 2009
63. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouyssegur J (2011) CD147 subunit of lactate/H+symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A 108:16663-16668
64. Boidot R, Vegran F, Meulle A, Lebreton A, Dessy C, Sonveaux P, Lizard-Nacol S, Feron O: Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors, Cancer Res 2011
65. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S, Zhou S, Diaz LA Jr, Velculescu VE, Lengauer C, Kinzler KW, Vogelstein B, Papadopoulos N (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325:1555-1559
66. Liapi E, Geschwind JF, Vali M, Khwaja AA, Prieto-Ventura V, Buijs M, Vossen JA, Ganapathy S, Wahl RL (2011) Assessment of tumoricidal efficacy and response to treatment with 18 F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. J Nucl Med 52:225-230
67. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Shanmugasundaram G, Syed L, Wahl RL, Geschwind JF (2008) Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther 327:32-37
68. Chang JM, Chung JW, Jae HJ, Eh H, Son KR, Lee KC, Park JH (2007) Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model. Acad Radiol 14:85-92 (Pubitemid 44920376)
69. Buijs M, Vossen JA, Geschwind JF, Ishimori T, Engles JM, Acha-Ngwodo O, Wahl RL, Vali M (2009) Specificity of the antiglycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs 27:120-123
70. Schaefer NG, Geschwind JF, Engles J, Buchanan JW, Wahl RL (2012) Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma. Transl Res 159:51-57
71. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P: Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells, Int J Biochem Cell Biol 2010
72. McCarty MF, Whitaker J (2010) Manipulating tumor acidification as a cancer treatment strategy. Altern Med Rev 15:264-272
73. Goodisman J, Hagrman D, Tacka KA, Souid AK (2006) Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 57:257-267 (Pubitemid 41779846)
74. Custodio JB, Cardoso CM, Santos MS, Almeida LM, Vicente JA, Fernandes MA (2009) Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents. Toxicology 259:18-24
75. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226:157-167 (Pubitemid 46428033)
76. Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364-369
77. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638-649 (Pubitemid 27171323)
78. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC (2007) Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81:495-504 (Pubitemid 47012464)